November 14 – 15, 2018 • Harvard Medical School, Boston, MA


Part I

The Infrastructure for Innovation

We need to make the transition to a predict, prevent and protect health system.

Joshua Ofman, M.D., M.S.H.S.
Senior Vice President, Global Value, Access and Policy, Amgen

*** Speakers will be added to the schedule on a rolling basis as they are confirmed. ***

7:00 a.m.
Registration and Continental Breakfast

Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115

8:00 a.m.
Opening Remarks

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

8:10 a.m.
Setting the Stage: Exploring the Promise of Personalized Medicine — A Keynote Address


8:40 a.m.
Shifting Systems: Identifying the Common Challenges and Notable Achievements of Government Efforts to Advance Personalized Medicine

Government executives have an enormous influence over the direction of health systems and can therefore play a role in developing personalized medicine — but they need to know what works and what doesn’t if their respective efforts to promote personalized medicine are going to succeed. With that in mind, government representatives from around the globe will explore the common challenges and notable achievements of government initiatives in personalized medicine during this panel discussion.

MODERATOR | Antonio L. Andreu, M.D., Ph.D., Scientific Director, European Infrastructure for Translational Medicine

Ora Dar, Ph.D., Senior Expert, National Research & Development Projects, Technological Infrastructure Division, Israel Innovation Authority

Tom Fowler, Ph.D., Deputy Chief Scientist, Genomics England

Liisa-Maria Voipio-Pulkki, M.D., Ph.D., Director General, Ministry of Social Affairs and Health, Finland

9:55 a.m.
Networking Break

Light refreshments provided.

10:40 a.m.
Evaluating the Patient Experience: Understanding Perspectives on Personalized Medicine

MODERATOR | Susan McClure, Founder, Publisher, Genome magazine

Bryce Olson, Global Marketing Director, Health and Life Sciences Group, Intel Corporation

11:10 a.m.
Automating Actionable: How Artificial Intelligence is Charting a Course for Personalized Medicine in Oncology and Beyond

Artificial intelligence presents new opportunities for researchers to identify how genes, proteins and other biological characteristics contribute to human disease, thereby informing personalized medicine. During this session, a diverse panel will separate knowledge from hype by discussing how artificial intelligence may accelerate drug development, improve clinical decision support, and drive patient outcomes in areas including but not limited to oncology and neurodegenerative diseases.

MODERATOR | William S. Dalton, Ph.D., M.D., Founder, Executive Chairman, M2Gen; Director, DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center

Colin Hill, Chairman, CEO, co-Founder, GNS Healthcare

Gregg Talbert, Ph.D., Global Head of Digital and Personalized Health Care Partnering, Roche

Darrell M. West, Ph.D., Vice President of Governance Studies, Director of the Center for Technology Innovation, Douglas Dillon Chair in Governance Studies, The Brookings Institution

12:25 p.m.
1:40 p.m.
Engaging Everyone: Leveraging Diversity and Facilitating Equitable Access to Personalized Care

Advancing a medical paradigm that focuses on the unique characteristics of each patient will require, by definition, that patients from diverse backgrounds participate in the medical studies that advance our understanding of disease and have access to personalized care informed by those studies. During this session, three panelists will discuss the effort to ensure that all patient populations benefit equally from personalized medicine.

MODERATOR | Donna R. Cryer, J.D., President, CEO, Global Liver Institute

Vence L. Bonham, J.D., Senior Advisor to the Director on Genomics and Health Disparities, U.S. National Human Genome Research Institute

Alex J. Carlisle, Ph.D., Chairman, CEO, National Alliance Against Disparities in Patient Health

Adolph P. Falcón, Executive Vice President, National Alliance for Hispanic Health

2:25 p.m.
Prospecting Policies: Understanding US Agencies’ Perspectives on the Use of Real-World Evidence and Digital Health to Facilitate Personalized Care

Government policies related to biomedical research, regulation, and reimbursement will determine whether health systems have the flexibility to leverage real-world evidence and digital health technologies to update personalized care regimens in real time. This panel of officials from the U.S. National Institutes of Health, the U.S. Food and Drug Administration, and the U.S. Centers for Medicare and Medicaid Services will discuss their respective perspectives on the use of these tools for the purposes of treatment development, label expansions, evidence generation, and patient empowerment.

MODERATOR | Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition

TBD representative, U.S. Food and Drug Administration

TBD representative, U.S. Centers for Medicare and Medicaid Services

TBD representative, U.S. National Institutes of Health

3:25 p.m.
Networking Break

Light refreshments provided.

4:10 p.m.
The Lay of the Lab: Exploring the State of the Diagnostics Industry — A Keynote Address

SPEAKER | David King, J.D., Chairman, CEO, LabCorp

4:40 p.m.
The Diagnostics Debate: Discussing the Extent to Which Existing Regulatory and Reimbursement Pathways for Diagnostic Tests Help or Hinder the Development of Personalized Medicine

The U.S. Food and Drug Administration and the U.S. Centers for Medicare and Medicaid Services have been working for over a decade to develop regulatory and reimbursement pathways that promote the development of innovative diagnostic tests. Many industry representatives, however, believe the current regulatory and reimbursement landscape limits the field. This panel of business leaders will discuss the extent to which the existing frameworks and proposed policies may help or hinder personalized medicine.


Julie Khani, President, American Clinical Laboratory Association

Kimberly Popovits, Chairman of the Board, CEO, President, Genomic Health

Mark P. Stevenson, Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific

TBD representative, Foundation Medicine

5:40 p.m.
Closing Remarks

SPEAKER | Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health

6:15 p.m.
Welcome Reception at the Isabella Stewart Gardner Museum

25 Evans Way
Boston, MA 02115

Welcome Reception

At the Isabella Stewart Gardner Museum

November 14, 2018 – 6:15 p.m.
25 Evans Way, Boston, MA 02115

We will convene for cocktails and hors d’oeuvres at the Isabella Stewart Gardner Museum immediately after the first day of conference programming. The museum is in walking distance from the Conference Center.

Sponsored by

6:05 p.m.
Sponsored by


Part II

The Business of Personalization

The successful implementation of [personalized medicine] will depend on the embrace of [its] principles in the business community.

Raju Kucherlapati, Ph.D.
Paul C. Cabot Professor of Genetics, Harvard Medical School

*** Speakers will be added to the schedule on a rolling basis as they are confirmed. ***

7:00 a.m.
Registration and Continental Breakfast

Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115

8:00 a.m.
Opening Remarks

SPEAKER | Stephen L. Eck, M.D., Ph.D., Chief Medical Officer, Immatics US Inc.

8:10 a.m.
Pioneering Precision: Inside the Pharmaceutical Industry’s Push Toward Personalized Medicine

MODERATOR | Meg Tirrell, Reporter, CNBC (invited)

Daniel O’Day, CEO, Roche Pharmaceuticals

8:40 a.m.
Considering Costs: Evaluating the Viability of Pharmaceutical and Insurance Industry Business Models in Personalized Medicine

The pharmaceutical industry is deeply invested in commercializing personalized therapies that must recoup development costs from smaller patient populations. In that context, this diverse panel will explore the viability of the business model for developing and paying for personalized medicines, tackling issues related to costs, prices, and access.

MODERATOR | Meg Tirrell, Reporter, CNBC (invited)

Nick Leschly, CEO, Bluebird Bio (invited)

Joshua Ofman, M.D., M.S.H.S., Senior Vice President, Global Value, Access and Policy, Amgen

Michael Sherman, M.D., M.B.A., M.S., Chief Medical Officer, Senior Vice President, Harvard Pilgrim Health Care

9:40 a.m.
The 14th Annual Leadership in Personalized Medicine Award

INTRODUCTION | Steven D. Averbuch, M.D., Vice President, Head of Precision Medicine, Bristol-Myers Squibb

AWARDEE | Ellen V. Sigal, Ph.D., Chairperson, Founder, Friends of Cancer Research

10:10 a.m.
Networking Break

Light refreshments provided.

10:40 a.m.
Defeating Disease: Evaluating How Personalized Medicine Can Help Patients Predict and Prevent Illness

The original architects of the personalized medicine paradigm envisioned an era in which clinicians could predict, prevent and treat disease based on an improved understanding of how human biology interacts with external environments. During this session, Ralph Snyderman, M.D., Chancellor Emeritus and James B. Duke Professor of Medicine, Duke University, will help us examine progress on each of these fronts during a wide-ranging conversation with another leader in the effort to advance personalized medicine.


Ralph Snyderman, M.D., Chancellor Emeritus, James B. Duke Professor of Medicine, Duke University


11:25 a.m.
Harvard Business School Case Study

LEADER | Richard Hamermesh, D.B.A., co-Faculty Chair, Harvard Business School Kraft Precision Medicine Accelerator

12:25 p.m.
Bag Lunch
1:25 p.m.
Assessing the Assays: Determining the Clinical and Economic Utility of Genetic Sequencing

Recognizing the need for evidence that underlines the value of the genetic sequencing tests that help make personalized medicine possible, the Personalized Medicine Coalition has commissioned research that examines the clinical and economic benefits of genetic sequencing for non-small cell lung cancer patients and patients with rare and undiagnosed diseases. During this session, researchers involved in those studies will discuss their work with payer representatives and the audience.

MODERATOR | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition

Aris Baras, M.D., Vice President, Regeneron Pharmaceuticals; Head, Regeneron Genetics Center

Kristine Bordenave, M.D., F.A.C.P., Lead Medical Director, Humana

Scott Ramsey, M.D., Ph.D., Member, Fred Hutchinson Cancer Research Center

2:25 p.m.
Impasse or Inflection Point? — An Investment Analysis

Sustaining the pace of innovation in personalized medicine will require continued investment in new initiatives, but the financial outlook for the field remains unclear. In that context, this panel of investors will examine whether personalized medicine is at an impasse, an inflection point, or somewhere in between.


Alexis Borisy, Partner, Third Rock Ventures (invited)

Gregory Dorn, M.D., President, Group Head, Hearst Health

Juan Enriquez, Managing Director, Excel Venture Management (invited)

Michael Pellini, M.D., Managing Partner, Section 32

3:25 p.m.
Closing Remarks

SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition